Summary: Facioscapulohumeral muscular dystrophy (FSHD), a dominantly inherited disorder, is the third most common dystrophy after Duchenne and myotonic muscular dystrophy. No known effective treatments exist for FSHD. The lack of an understanding of the underlying pathophysiology remains an obstacle in the development of targeted therapeutic interventions. The genetic defect is a loss of a critical number of a repetitive element (D4Z4) in the 4q subtelomeric region. The loss of the repeats results in specific changes in chromatin structure, although neither the molecular nor the cellular consequences of this change are known. Nevertheless, these epigenetic changes in chromatin structure offer a potential therapeutic target. This review discusses current management strategies in FSHD as well as potential therapeutic interventions to slow down or reverse the progressive muscle atrophy and weakness.
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly inherited dystrophy, with a prevalence of 1:20,000, 1 and is the third most common dystrophy after the dystrophinopathies and myotonic dystrophy.
CLINICAL MANIFESTATIONS
FSHD is characterized by onset of weakness in an initially restricted and characteristic distribution, starting with facial weakness, which is often mild and asymptomatic, and followed sequentially by scapular fixator, humeral, truncal, and lower-extremity weakness. The most common initial symptom is difficulty reaching above shoulder level, related to weakness of the scapular fixators. The clinical severity is wide ranging, from asymptomatic individuals to individuals who are wheelchair-dependent. Extraocular and bulbar muscles are typically spared in FSHD, and symptomatic respiratory weakness occurs in only approximately 1% of affected individuals.
2 Extramuscular manifestations also occur in FSHD, the most common being mild high-frequency hearing loss and asymptomatic retinal telangiectasias, which occur in 75% and 60% of affected individuals, respectively. 3, 4 Rarely, in severely affected individuals, the retinal vascular abnormalities can cause potentially catastrophic retinal exudation leading to retinal detachment (Coats disease).
5 Cardiac involvement, manifesting as a predilection to atrial arrhythmias, is seen in approximately 5% of patients, few of whom require treatment.
6

GENETICS
Genetic defect in FSHD
FSHD results from a deletion of a repetitive element on 4q35 known as D4Z4. In healthy individuals, the D4Z4 repeat consists of 11 to 100 D4Z4 repeats, each 3.3 kb in size. Patients with autosomal-dominant FSHD, however, carry one array of 1 to 10 units (FIG. 1) . 7 There is an inverse relationship between the residual repeat number and the age at onset and severity of disease. 8, 9 Nonetheless, affected individuals within the same family, and carrying the same size deletion, can show a wide spectrum of severity, indicating that deletion size is not the only determinant of severity. Monosomy of 4q does not cause FSHD, suggesting that the FSHD-associated deletion leads to a deleterious gain of function.
10
Molecular mechanism in FSHD
Despite identification of the genetic defect associated with FSHD, the pathologic effects of this deletion remain largely unknown. The simplest and most parsimonious explanation is that loss of a critical number of D4Z4 repeats compromises the structure of an FSHD gene located within the repeats. Each D4Z4 repeat contains a single open reading frame encoding a putative double homeobox gene, designated DUX4.
11-13 However, in vivo expression of DUX4 has never been clearly established, despite recent evidence that the DUX4 is evolutionarily conserved.
14 An alternative hypothesis is that the FSHD-associated contraction influences the transcription, in cis, of genes proximal to the repeats on 4q35; however, definitive proof that proximal 4q35 genes are dysregulated remains elusive.
One such candidate gene is FRG1, 15 located 120 kb from the repeats. This gene encodes an evolutionarily highly conserved nuclear protein that may play a role in RNA biogenesis. 16, 17 Its expression in FSHD muscle is highly controversial.
15,18-21 Investigations by Gabellini et al. 18 found significant upregulation of FRG1 in FSHD muscle that was attributed to the loss of transcriptional repressor complexes that are present on the D4Z4 repeats; the group went on to demonstrate that transgenic mice overexpressing FRG1 at very high levels develop a myopathy. Other investigators have failed to confirm FRG1 upregulation in either FSHD muscle or FSHD myoblast cell line.
19-21 These contradictory findings make it uncertain as to whether the FRG1-overexpressing mouse is a valid animal model of FSHD. Nevertheless, there are a number of features of the D4Z4 repeats and their flanking regions that are altered by contraction of the D4Z4 repeats, indicating that they play a role in epigenetic control of gene expression. Moreover, such control may be exerted not only in cis on chromosome 4q, but potentially in trans on other chromosomes (FIG. 1) . These features include the preferential localization of 4q35 to the nuclear membrane, the presence of nuclear matrix attachment sites proximal to the repeats, and specific hypomethylation patterns in the contracted repeats.
22-24
DIAGNOSIS
Clinical diagnosis of FSHD can be made with relative certainty in most patients given the distinctive pattern of muscular involvement within the setting of an autosomaldominant family history. The diagnosis is confirmed with molecular diagnosis, bypassing the need for muscle biopsy in most instances. Standard molecular testing for FSHD demonstrates the presence of a contraction of the D4Z4 repeats in one copy of 4q35. The normal allele size of the DNA fragment detected by probe p13E-11 after EcoRI digestion is greater than 50 kb. Individuals with FSHD have one allele that is between 10 and 38 kb. The standard testing procedure performed by most laboratories is highly sensitive (95%) and specific (95%).
25,26
TREATMENT
Given that the underlying pathophysiology of FSHD remains uncertain, no disease-specific therapeutic strategies are possible at the present time. A number of nonpharmacologic interventions can provide symptomatic and functional improvement, as well as preventing known complications of the disease.
FIG. 1.
The subtelomeric region of chromosome 4q35 in normal individuals and in those with facioscapulohumeral muscular dystrophy (FSHD). Normal individuals have between 11 and 100 D4Z4 repeats on both 4q35 alleles, whereas individuals with FSHD have less than 11 repeats in one 4q35 allele. Possible consequences of the deletion include (A) activation of expressed sequences within D4Z4 (DUX4), (B) altered regulation of genes, in cis, on 4q35 proximal to the deletion, FRG1 being the leading candidate gene, or (C) altered regulation of genes, in trans, on other chromosomes.
